ES2088933T3 - Derivados de pirazol, procedimientos para su preparacion y composicion farmaceutica que los contiene. - Google Patents

Derivados de pirazol, procedimientos para su preparacion y composicion farmaceutica que los contiene.

Info

Publication number
ES2088933T3
ES2088933T3 ES90117983T ES90117983T ES2088933T3 ES 2088933 T3 ES2088933 T3 ES 2088933T3 ES 90117983 T ES90117983 T ES 90117983T ES 90117983 T ES90117983 T ES 90117983T ES 2088933 T3 ES2088933 T3 ES 2088933T3
Authority
ES
Spain
Prior art keywords
amino
acyl
halogen
alkylsulfinyl
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90117983T
Other languages
English (en)
Inventor
Masaaki Matsuo
Kiyoshi Tsuji
Nobukiyo Konishi
Katsuya Nakamura
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astellas Pharma Inc
Original Assignee
Fujisawa Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB898921466A external-priority patent/GB8921466D0/en
Priority claimed from GB909008399A external-priority patent/GB9008399D0/en
Application filed by Fujisawa Pharmaceutical Co Ltd filed Critical Fujisawa Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ES2088933T3 publication Critical patent/ES2088933T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

UN COMPUESTO DE LA FORMULA: EN DONDE R1 ES ARIL QUE PUEDE SUSTITUIR CON SUBSTITUTOS (S) SELECCIONADOS DESDE EL GRUPO QUE CONSISTE EN BAJO ALQUIL, HALOGENOS BAJO ALCOXI, BAJO ALQUITIO, BAJO ALQUISULFINIL, ALQUIL SULFONIL, HIDROXI, BAJO ALQUILSULFONILOXI, NITRATO, AMINO, BAJO ALQUILAMINO, ACILAMINO Y BAJO ALQUIL(ACIL)ANINO; O UN GRUPO HETEROCICLICO; R2 ES HIDROGENO; CON MENTIL QUE SUBTITUIDO CON AMINO, BAJO ALQUILAMINO, ACILAMINO, BAJO ALQUIL(ACIL)AMINO, BAJO ALCOXI, CIANO, HIDROXI O ACIL; O UN GRUPO HETEROCICLICO QUE PUEDE SER SUSTITUIDO CON UN BAJO ALQUITIO, BAJO ALQUILSULFINIL, BAJO ALQUILSULFONIL; CON PROVISION SEGURA Y SALES FARMACEUTICAS ACEPTABLES ASI MISMAS, PROCESO PARA SU PREPARACION Y COMPUESTOS FARMACEUTICOS COMPRENDIENDOLOS COMO UN INGREDIENTE ACTIVO
ES90117983T 1989-09-22 1990-09-19 Derivados de pirazol, procedimientos para su preparacion y composicion farmaceutica que los contiene. Expired - Lifetime ES2088933T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB898921466A GB8921466D0 (en) 1989-09-22 1989-09-22 Pyrazole derivatives,processes for preparation thereof and pharmaceutical composition comprising the same
GB909008399A GB9008399D0 (en) 1990-04-12 1990-04-12 Pyrazole derivatives,processes for preparation thereof and pharmaceutical composition comprising the same

Publications (1)

Publication Number Publication Date
ES2088933T3 true ES2088933T3 (es) 1996-10-01

Family

ID=26295958

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90117983T Expired - Lifetime ES2088933T3 (es) 1989-09-22 1990-09-19 Derivados de pirazol, procedimientos para su preparacion y composicion farmaceutica que los contiene.

Country Status (20)

Country Link
US (1) US5134142A (es)
EP (1) EP0418845B1 (es)
JP (1) JP2586713B2 (es)
KR (1) KR0182798B1 (es)
CN (1) CN1046506C (es)
AT (1) ATE126216T1 (es)
AU (1) AU637142B2 (es)
CA (1) CA2025599C (es)
DE (1) DE69021472T2 (es)
DK (1) DK0418845T3 (es)
ES (1) ES2088933T3 (es)
FI (1) FI102535B1 (es)
GR (1) GR3017100T3 (es)
HU (2) HU208122B (es)
IE (1) IE68857B1 (es)
IL (1) IL95675A (es)
NO (1) NO301006B1 (es)
PH (1) PH27357A (es)
PT (1) PT95389B (es)
RU (2) RU2021990C1 (es)

Families Citing this family (220)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU616564B2 (en) * 1988-09-29 1991-10-31 Sumitomo Chemical Company, Limited Novel pyrazole compounds, method for production thereof, use thereof and intermediates for production thereof
DE4039733A1 (de) * 1990-12-13 1992-06-17 Basf Ag Substituierte 5-aminopyrazole
NO179282C (no) * 1991-01-18 1996-09-11 Rhone Poulenc Agrochimie Nye 1-(2-pyridyl)pyrazolforbindelser til kontroll av skadeinsekter
AU1988692A (en) * 1991-04-24 1992-12-21 E.I. Du Pont De Nemours And Company Fungicidal pyrazoles, pyrazolines and tetrahydropyridazines
FR2682379B1 (fr) * 1991-10-09 1994-02-11 Rhone Poulenc Agrochimie Nouveaux phenylpyrazoles fongicides.
IL104311A (en) * 1992-02-05 1997-07-13 Fujisawa Pharmaceutical Co Pyrazole derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
US5550147A (en) * 1992-02-05 1996-08-27 Fujisawa Pharmaceutical Co., Ltd. Pyrazole derivatives, processes for preparation thereof and pharmaceutical composition comprising the same
FR2690440B1 (fr) * 1992-04-27 1995-05-19 Rhone Poulenc Agrochimie Arylpyrazoles fongicides.
FR2692575B1 (fr) * 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
FR2713225B1 (fr) * 1993-12-02 1996-03-01 Sanofi Sa N-pipéridino-3-pyrazolecarboxamide substitué.
US6492413B2 (en) 1993-01-15 2002-12-10 G.D. Searle & Co. 3.4-diaryl thiophenes and analogs thereof having use as antiinflammatory agents
GB9420616D0 (en) * 1994-10-12 1994-11-30 Merck Sharp & Dohme Method, compositions and use
US5380738A (en) * 1993-05-21 1995-01-10 Monsanto Company 2-substituted oxazoles further substituted by 4-fluorophenyl and 4-methylsulfonylphenyl as antiinflammatory agents
US5840746A (en) * 1993-06-24 1998-11-24 Merck Frosst Canada, Inc. Use of inhibitors of cyclooxygenase in the treatment of neurodegenerative diseases
US5474995A (en) * 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
US5387602A (en) * 1993-08-30 1995-02-07 Ortho Pharmaceutical Corporation 1.5-diphenyl-3-(N-hydroxycarbamoyloxyalkyl)pyrazoles
FR2711140B1 (fr) * 1993-10-12 1996-01-05 Sanofi Sa 1-Naphtylpyrazole-3-carboxamides substitués actifs sur la neurotensine, leur préparation, les compositions pharmaceutiques en contenant.
US5434178A (en) * 1993-11-30 1995-07-18 G.D. Searle & Co. 1,3,5 trisubstituted pyrazole compounds for treatment of inflammation
US6492411B1 (en) 1993-11-30 2002-12-10 G. D. Searle & Co. Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation
US6716991B1 (en) 1993-11-30 2004-04-06 G. D. Searle & Co. Process for preparing a substituted pyrazolyl benzenesulfonamide for the treatment of inflammation
US5475018A (en) * 1993-11-30 1995-12-12 G. D. Searle & Co. 1,5-diphenyl pyrazole compounds for treatment of inflammation
US5401765A (en) * 1993-11-30 1995-03-28 G. D. Searle 1,4,5-triphenyl pyrazolyl compounds for the treatment of inflammation and inflammation-related disorders
CA2277954A1 (en) * 1993-11-30 1995-06-08 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation
US5466823A (en) * 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
US5500439A (en) * 1993-12-09 1996-03-19 Alteon Inc. Aminopyrazoles
US5486534A (en) * 1994-07-21 1996-01-23 G. D. Searle & Co. 3,4-substituted pyrazoles for the treatment of inflammation
US5908852A (en) * 1994-11-14 1999-06-01 G. D. Searle & Co. 1,3,5 trisubstituted pyrazole compounds for treatment of inflammation
JP2636819B2 (ja) 1994-12-20 1997-07-30 日本たばこ産業株式会社 オキサゾール系複素環式芳香族化合物
CA2222138C (en) * 1995-05-25 2008-10-14 G.D. Searle & Co. Method of preparing 3-haloalkyl-1h-pyrazoles
US6515014B2 (en) 1995-06-02 2003-02-04 G. D. Searle & Co. Thiophene substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors
US6512121B2 (en) 1998-09-14 2003-01-28 G.D. Searle & Co. Heterocyclo substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors
CA2223154A1 (en) * 1995-06-02 1996-12-05 G.D. Searle & Co. Heterocyclo substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors
US5756529A (en) * 1995-09-29 1998-05-26 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides for use in veterinary therapies
GB9520584D0 (en) * 1995-10-09 1995-12-13 Fujisawa Pharmaceutical Co Pyrazole derivatives,processes for preparation thereof and pharmaceutical composition comprising the same
FR2742148B1 (fr) * 1995-12-08 1999-10-22 Sanofi Sa Nouveaux derives du pyrazole-3-carboxamide, procede pour leur preparation et compositions pharmaceutiques les contenant
US5908858A (en) * 1996-04-05 1999-06-01 Sankyo Company, Limited 1,2-diphenylpyrrole derivatives, their preparation and their therapeutic uses
US6677364B2 (en) * 1998-04-20 2004-01-13 G.D. Searle & Co. Substituted sulfonylphenylheterocycles as cyclooxygenase-2 and 5-lipoxygenase inhibitors
CA2275796A1 (en) * 1996-12-23 1998-07-02 Donald Joseph Phillip Pinto Nitrogen containing heteroaromatics as factor xa inhibitors
AU736282B2 (en) 1997-03-21 2001-07-26 Chugai Seiyaku Kabushiki Kaisha A preventive or therapeutic agent for sensitized T cell- mediated diseases comprising IL-6 antagonist as an active ingredient
US6979686B1 (en) 2001-12-07 2005-12-27 Pharmacia Corporation Substituted pyrazoles as p38 kinase inhibitors
US6087496A (en) * 1998-05-22 2000-07-11 G. D. Searle & Co. Substituted pyrazoles suitable as p38 kinase inhibitors
US5932576A (en) * 1997-05-22 1999-08-03 G. D. Searle & Company 3(5)-heteroaryl substituted pyrazoles as p38 kinase inhibitors
US6514977B1 (en) * 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
US6087381A (en) * 1997-05-22 2000-07-11 G. D. Searle & Company Pyrazole derivatives as p38 kinase inhibitors
US5998424A (en) 1997-06-19 1999-12-07 Dupont Pharmaceuticals Company Inhibitors of factor Xa with a neutral P1 specificity group
HRP980334A2 (en) * 1997-06-19 1999-04-30 Mimi Lifen Quan INHIBITORS OF FACTOR Xa WITH A NEUTRAL P1 SPECIFICITY GROUP
AU750356B2 (en) * 1997-09-24 2002-07-18 Fujisawa Pharmaceutical Co., Ltd. 1,5-diphenylpyrazole derivatives
AUPO941497A0 (en) * 1997-09-24 1997-10-16 Fujisawa Pharmaceutical Co., Ltd. Novel compounds
AU751139B2 (en) * 1997-10-13 2002-08-08 Astellas Pharma Inc. Amide derivative
AUPP042397A0 (en) * 1997-11-18 1997-12-11 Fujisawa Pharmaceutical Co., Ltd. 5-arylpyrazole compounds
ES2137138B1 (es) * 1998-05-29 2000-09-16 Esteve Labor Dr Derivados de pirazolinas, su preparacion y su aplicacion como medicamentos.
AU4225499A (en) * 1998-06-03 1999-12-20 Merck & Co., Inc. Hiv integrase inhibitors
US6306891B1 (en) 1998-06-03 2001-10-23 Merck & Co., Inc. HIV integrase inhibitors
US6262055B1 (en) * 1998-06-03 2001-07-17 Merck & Co., Inc. HIV integrase inhibitors
US6380249B1 (en) 1998-06-03 2002-04-30 Merck & Co., Inc. HIV integrase inhibitors
US6506747B1 (en) * 1998-06-05 2003-01-14 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted 1-(4-aminophenyl)pyrazoles and their use as anti-inflammatory agents
TNSN99111A1 (fr) * 1998-06-11 2005-11-10 Pfizer Derives de sulfonylbenzene nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant.
US6727238B2 (en) 1998-06-11 2004-04-27 Pfizer Inc. Sulfonylbenzene compounds as anti-inflammatory/analgesic agents
US6294558B1 (en) 1999-05-31 2001-09-25 Pfizer Inc. Sulfonylbenzene compounds as anti-inflammatory/analgesic agents
DE19831656A1 (de) * 1998-07-15 2000-01-20 Basf Ag Verfahren zur Herstellung von Pyrazolen
CA2338490A1 (en) 1998-07-27 2000-02-10 Sergio Altamura Diketoacid-derivatives as inhibitors of polymerases
GB9816358D0 (en) * 1998-07-27 1998-09-23 Angeletti P Ist Richerche Bio Enzyme inhibitors
USRE39708E1 (en) 1998-08-07 2007-06-26 Chiron Corporation Estrogen receptor modulators
US6291190B1 (en) * 1998-08-25 2001-09-18 The Board Of Trustees Of The Leland Stanford Junior University Molecular differences between species of the M. tuberculosis complex
US6191147B1 (en) * 1998-12-24 2001-02-20 Ppd Discovery, Inc. Pyrazole compounds and uses thereof
BR9916583A (pt) 1998-12-25 2001-09-25 Shionogi & Co Derivados heteroaromáticos tendo uma atividade inibitória contra integrase de hiv
DE19904397A1 (de) * 1999-02-04 2000-08-10 Bayer Ag Verwendung von Pyrazol-Carbonsäureamiden
IL145508A0 (en) * 1999-03-26 2002-06-30 Euro Celtique Sa Aryl substituted pyrazole, imidazole, oxazole, thiazole and pyrrole derivatives and pharmaceutical compositions containing the same
ATE267830T1 (de) * 1999-08-27 2004-06-15 Abbott Lab Als cox-hemmer verwendbare sulfonylphenylpyrazol- verbindungen
DK1104758T3 (da) 1999-12-03 2003-10-20 Pfizer Prod Inc Acetylenderivativer som anti-inflammatoriske/analgesiske lægemidler
TR200302047T4 (tr) 1999-12-03 2004-01-21 Pfizer Products Inc. Anti-iltihabik / analjezik maddeler olarak heteroaril fenil pirazol bileşikleri.
DK1104760T3 (da) 1999-12-03 2003-06-30 Pfizer Prod Inc Sulfamoylheteroarylpyrazolforbindelser som anti-inflammatoriske/analgetiske midler
DE60018792T2 (de) 1999-12-03 2006-01-26 Pfizer Products Inc., Groton Heterocyclo-alkylsulfonylpyrazolderivate zur verwendung als anti-imflammatorische oder analgetische verbindungen
US6569885B1 (en) * 1999-12-23 2003-05-27 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
US6372752B1 (en) * 2000-02-07 2002-04-16 Genzyme Corporation Inha inhibitors and methods of use thereof
WO2001064669A1 (en) 2000-03-03 2001-09-07 Pfizer Products Inc. Pyrazole ether derivatives as anti-inflammatory/analgesic agents
EP1292577B1 (en) * 2000-03-24 2012-10-24 Euro-Celtique S.A. Aryl substituted pyrazoles, triazoles and tetrazoles as sodium channel blocker
WO2002055502A1 (en) * 2001-01-02 2002-07-18 Fujisawa Pharmaceutical Co., Ltd. Pyridine derivatives useful as cyclooxygenase inhibitor
US20030105144A1 (en) 2001-04-17 2003-06-05 Ping Gao Stabilized oral pharmaceutical composition
US6673818B2 (en) * 2001-04-20 2004-01-06 Pharmacia Corporation Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation
US7041685B2 (en) * 2001-06-08 2006-05-09 Cytovia, Inc. Substituted 3-aryl-5-aryl-[1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis and the use thereof
ES2241964T3 (es) 2001-07-05 2005-11-01 Pfizer Products Inc. Heterocicloalquilsulfufonilpirazoles como agentes antiinflamatorios/abnalgesicos.
US7076539B2 (en) * 2001-07-30 2006-07-11 Hewlett-Packard Development Company, L.P. Network connectivity establishment at user log-in
JP2005507892A (ja) * 2001-09-19 2005-03-24 ファルマシア・コーポレーション 炎症の治療のための置換されたピラゾリルベンゼンスルファミド化合物
EP1444207A2 (en) * 2001-09-19 2004-08-11 Pharmacia Corporation Substituted pyrazolyl-compounds for the treatment of inflammation
YU30504A (sh) 2001-09-25 2006-08-17 Pharmacia Corporation Postupak za dobijanje supstituisanih pirazola
US7057049B2 (en) * 2001-09-25 2006-06-06 Pharmacia Corporation Process for making substituted pyrazoles
RU2277534C2 (ru) * 2001-09-25 2006-06-10 Фармация Корпорейшн Способ получения замещенных пиразолов
GT200200183A (es) 2001-09-28 2003-05-23 Procedimiento para preparar derivados de heterocicloalquilsulfonil pirazol
WO2003037336A1 (en) 2001-11-02 2003-05-08 Pfizer Products Inc. 1-(5-sulfonyl-pyridin-2-yl)-5-(methylidene-cycloalkylmethoxy)-1h-pyrazole-4-carbonitrile derivatives and other compounds as cyclooxygenase inhibitors for the treatment of arthritis, neurodegeneration and colon cancer
ATE424388T1 (de) 2001-12-06 2009-03-15 Merck & Co Inc Mitotische kinesinhemmer
HK1079785B (zh) * 2002-03-05 2007-08-10 辛根塔参与股份公司 邻环丙基-n-甲酰苯胺及其作为杀菌剂的用途
EP1492487B1 (en) * 2002-03-08 2009-11-11 Merck & Co., Inc. Mitotic kinesin inhibitors
AR038967A1 (es) * 2002-03-18 2005-02-02 Solvay Pharm Bv Derivados de 2,3 - diaril - pirazolidinas como inhibidores de enzimas que degradan la neurotensina
US7329401B2 (en) * 2002-04-15 2008-02-12 The Regents Of The University Of California Cyclooxygenase-2 selective agents useful as imaging probes and related methods
CN100348586C (zh) 2002-05-24 2007-11-14 法玛西雅公司 二芳基吡唑的合成方法
IL165624A0 (en) * 2002-06-14 2006-01-15 Merck & Co Inc Mitotic kinesin inhibitors
JP2005535642A (ja) * 2002-06-28 2005-11-24 ニトロメッド インコーポレーティッド オキシムおよび／またはヒドラゾンを含有するニトロソ化および／またはニトロシル化シクロオキシゲナーゼ−２選択的阻害剤、組成物、および使用方法
US6649638B1 (en) * 2002-08-14 2003-11-18 Ppd Discovery, Inc. Prenylation inhibitors and methods of their synthesis and use
WO2004016741A2 (en) * 2002-08-14 2004-02-26 Ppd Discovery, Inc. Prenylation inhibitors containing dimethyl-cyclobutane and methods of their synthesis and use
WO2004016592A1 (en) * 2002-08-14 2004-02-26 Ppd Discovery, Inc. Prenylation inhibitors and methods of their synthesis and use
BR0314872A (pt) * 2002-10-18 2005-08-02 Pfizer Prod Inc Ligandos do receptor canabinóide e usos dos mesmos
US7129239B2 (en) * 2002-10-28 2006-10-31 Pfizer Inc. Purine compounds and uses thereof
WO2004050632A1 (en) * 2002-12-02 2004-06-17 Fujisawa Pharmaceutical Co., Ltd. Pyrazole derivatives useful as cox-i inhibitors
US7247628B2 (en) * 2002-12-12 2007-07-24 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
JP2006516250A (ja) * 2002-12-18 2006-06-29 サイトビア インコーポレイティッド カスパーゼ活性化剤およびアポトーシス誘導物質としての３，５−二置換−［１，２，４］−オキサジアゾールおよびそれらの誘導体ならびにそれらの使用
US7329658B2 (en) * 2003-02-06 2008-02-12 Pfizer Inc Cannabinoid receptor ligands and uses thereof
RU2332412C2 (ru) * 2003-02-07 2008-08-27 Дайити Фармасьютикал Ко., Лтд. Производные пиразола
CN100436445C (zh) * 2003-02-07 2008-11-26 第一制药株式会社 吡唑衍生物
US7176210B2 (en) * 2003-02-10 2007-02-13 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
US20040214856A1 (en) * 2003-04-23 2004-10-28 Pfizer Inc Cannabinoid receptor ligands and uses thereof
US7141669B2 (en) * 2003-04-23 2006-11-28 Pfizer Inc. Cannabiniod receptor ligands and uses thereof
US7145012B2 (en) * 2003-04-23 2006-12-05 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
US7268133B2 (en) * 2003-04-23 2007-09-11 Pfizer, Inc. Patent Department Cannabinoid receptor ligands and uses thereof
CA2524397A1 (en) * 2003-05-07 2004-11-18 Pfizer Products Inc. Cannabinoid receptor ligands and uses thereof
US7232823B2 (en) 2003-06-09 2007-06-19 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
US20040259887A1 (en) * 2003-06-18 2004-12-23 Pfizer Inc Cannabinoid receptor ligands and uses thereof
CA2533889A1 (en) 2003-08-15 2005-03-03 Merck & Co., Inc. Mitotic kinesin inhibitors
US7638549B2 (en) 2003-08-15 2009-12-29 Merck & Co. Inc. Mitotic kinesin inhibitors
US20060079566A1 (en) * 2003-10-03 2006-04-13 Ching-Shih Chen PDK-1/Akt signaling inhibitors
TW200526641A (en) * 2003-12-26 2005-08-16 Daiichi Seiyaku Co Amidopyrazole derivatives
JP2007084437A (ja) * 2003-12-26 2007-04-05 Dai Ichi Seiyaku Co Ltd アミノアルキルピラゾール誘導体
CA2571824A1 (en) * 2004-07-01 2006-01-19 Merck & Co., Inc. Mitotic kinesin inhibitors
MXPA06015275A (es) 2004-07-01 2007-03-15 Merck & Co Inc Inhibidores de quinasa mitotica.
JP2008505089A (ja) * 2004-07-01 2008-02-21 メルク　エンド　カムパニー　インコーポレーテッド 有糸分裂キネシン阻害剤
WO2006007497A2 (en) * 2004-07-01 2006-01-19 Merck & Co., Inc. Prodrugs of mitotic kinesin inhibitors
JPWO2006013962A1 (ja) * 2004-08-06 2008-05-01 第一製薬株式会社 抗血小板薬およびその製造方法
JPWO2006014005A1 (ja) * 2004-08-06 2008-05-01 第一製薬株式会社 ピラゾール誘導体
EP1868601A4 (en) * 2005-04-07 2008-12-10 Merck & Co Inc MITOTIC KINESINE HEMMER
ATE550019T1 (de) 2005-05-17 2012-04-15 Merck Sharp & Dohme Cis-4-ä(4-chlorophenyl)sulfonylü-4-(2,5- difluorophenyl)cyclohexanepropansäure zur behandlug von krebs
WO2006133926A1 (en) * 2005-06-17 2006-12-21 Carex Sa Pyrazole derivates as cannabinoid receptor modulators
KR101363278B1 (ko) 2005-06-27 2014-02-21 엑셀리시스 페이턴트 컴퍼니 엘엘씨 이미다졸계 ｌｘｒ 변조제
PE20070335A1 (es) * 2005-08-30 2007-04-21 Novartis Ag Benzimidazoles sustituidos y metodos para su preparacion
WO2007087246A2 (en) 2006-01-24 2007-08-02 Merck & Co., Inc. Jak2 tyrosine kinase inhibition
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
KR101464385B1 (ko) 2006-04-19 2014-11-21 노파르티스 아게 ６-ｏ-치환된 벤즈옥사졸 및 벤조티아졸 화합물, 및 ｃｓｆ-１ｒ 신호전달의 억제 방법
AU2007300627B2 (en) 2006-09-22 2012-02-16 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
WO2008039023A1 (en) * 2006-09-29 2008-04-03 Green Cross Corporation Heteroaryl-pyrazole derivatives as cannabinoid cb1 receptor antagonists
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
BRPI0806245B1 (pt) 2007-01-10 2022-01-25 Msd Italia S.R.L. Compostos de fórmula i e seus usos
CN101626787A (zh) * 2007-01-19 2010-01-13 马林克罗特公司 诊断的和治疗的环氧合酶-2结合配体
US20080207704A1 (en) * 2007-02-27 2008-08-28 The Green Cross Corporation Heteroaryl-imidazole derivatives as cannabinoid cb1 receptor antagonists
CN101679266B (zh) 2007-03-01 2015-05-06 诺华股份有限公司 Pim激酶抑制剂及其应用方法
US20100120839A1 (en) * 2007-04-20 2010-05-13 Biolipox Ab Pyrazoles useful in the treatment of inflammation
AU2008254425A1 (en) 2007-05-21 2008-11-27 Novartis Ag CSF-1R inhibitors, compositions, and methods of use
WO2008145257A1 (en) * 2007-05-31 2008-12-04 Syngenta Participations Ag Process for the production of pyrazoles
WO2009002495A1 (en) 2007-06-27 2008-12-31 Merck & Co., Inc. 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
US8039502B2 (en) 2007-07-24 2011-10-18 The Ohio State University Research Foundation Anti-infective agents against intracellular pathogens
US7977358B2 (en) * 2007-07-26 2011-07-12 Hoffmann-La Roche Inc. Pyrazol derivatives
RU2465272C2 (ru) 2007-09-10 2012-10-27 КалсиМедика, Инк. Соединения, моделирующие внутриклеточный кальций
US20110009463A1 (en) * 2007-10-17 2011-01-13 Yuri Karl Petersson Geranylgeranyl transferase inhibitors and methods of making and using the same
WO2009078498A1 (en) * 2007-12-17 2009-06-25 Green Cross Corporation Biarylpyrazole 4-carboxamides as cannabinoid cb1 receptor ligands
WO2009094224A1 (en) 2008-01-25 2009-07-30 Millennium Pharmaceuticals, Inc. Thiophenes and their use as phosphatidylinositol 3-kinase (pi3k) inhibitors
US8598184B2 (en) 2008-03-03 2013-12-03 Tiger Pharmatech Protein kinase inhibitors
DE102008015033A1 (de) * 2008-03-17 2009-09-24 Aicuris Gmbh & Co. Kg Substituierte (Pyrazolyl-carbonyl)imidazolidinone und ihre Verwendung
DE102008015032A1 (de) * 2008-03-17 2009-09-24 Aicuris Gmbh & Co. Kg Substituierte Pyrazolamide und ihre Verwendung
ES2714453T3 (es) * 2008-06-09 2019-05-28 Univ Muenchen Ludwig Maximilians Fármacos para inhibir la agregación de proteínas implicadas en enfermedades relacionadas con enfermedades neurodegenerativas y/o agregación de proteínas
WO2009151991A1 (en) * 2008-06-11 2009-12-17 Merck & Co., Inc. Pyrazole derivatives useful as inhibitors of faah
CA2734500A1 (en) 2008-08-27 2010-03-11 Calcimedica Inc. Compounds that modulate intracellular calcium
DE102008062863A1 (de) 2008-12-17 2010-06-24 Aicuris Gmbh & Co. Kg Substituierte (Thiophenyl-carbonyl)imidazolidinone und ihre Verwendung
DE102008062878A1 (de) 2008-12-17 2010-06-24 Aicuris Gmbh & Co. Kg Substituierte Furancarboxamide und ihre Verwendung
US8796314B2 (en) 2009-01-30 2014-08-05 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
JP2012516329A (ja) 2009-01-30 2012-07-19 ミレニアム ファーマシューティカルズ， インコーポレイテッド Ｐｉ３ｋ阻害剤としてのヘテロアリールおよびその使用
US9090601B2 (en) 2009-01-30 2015-07-28 Millennium Pharmaceuticals, Inc. Thiazole derivatives
US20120108823A1 (en) 2009-04-22 2012-05-03 The Ohio State University Research Foundation Anti-francisella agents
DE102009036604A1 (de) 2009-07-30 2011-02-03 Aicuris Gmbh & Co. Kg Substituierte Bis-Arylpyrazolamide mit terminaler primärer Amidfunktionalisierung und ihre Verwendung
CA2777043C (en) 2009-10-14 2015-12-15 Schering Corporation Substituted piperidines that increase p53 activity and the uses thereof
JP6112486B2 (ja) 2010-04-27 2017-04-12 カルシメディカ，インク． 細胞内カルシウムを調節する化合物
EP2563759B1 (en) 2010-04-27 2022-04-06 Calcimedica, Inc. Compounds that modulate intracellular calcium
EP2584903B1 (en) 2010-06-24 2018-10-24 Merck Sharp & Dohme Corp. Novel heterocyclic compounds as erk inhibitors
CN103068980B (zh) 2010-08-02 2017-04-05 瑟纳治疗公司 使用短干扰核酸（siNA）的RNA干扰介导的联蛋白（钙粘蛋白关联蛋白质），β1（CTNNB1）基因表达的抑制
US8859768B2 (en) 2010-08-11 2014-10-14 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
US9062038B2 (en) 2010-08-11 2015-06-23 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
EP2603214A4 (en) 2010-08-11 2013-12-18 Millennium Pharm Inc HETEROARYLE AND USES THEREOF
RU2745848C2 (ru) 2010-08-17 2021-04-01 Сирна Терапьютикс, Инк. ОПОСРЕДУЕМОЕ РНК-ИНТЕРФЕРЕНЦИЕЙ ИНГИБИРОВАНИЕ ЭКСПРЕССИИ ГЕНОВ ВИРУСА ГЕПАТИТА B (HBV) С ПРИМЕНЕНИЕМ МАЛОЙ ИНТЕРФЕРИРУЮЩЕЙ НУКЛЕИНОВОЙ КИСЛОТЫ (миНК)
US8883801B2 (en) 2010-08-23 2014-11-11 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
CN103180316A (zh) 2010-08-27 2013-06-26 钙医学公司 调节细胞内钙的化合物
US8580805B2 (en) * 2010-08-31 2013-11-12 Hubert Maehr Pyrimidine carboxamide derivatives
EP2613782B1 (en) 2010-09-01 2016-11-02 Merck Sharp & Dohme Corp. Indazole derivatives useful as erk inhibitors
US9242981B2 (en) 2010-09-16 2016-01-26 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel ERK inhibitors
MX2013004003A (es) 2010-10-13 2013-10-01 Millenium Pharmaceuticals Inc Heteroarilos y usos de los mismos.
WO2012058210A1 (en) 2010-10-29 2012-05-03 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA)
WO2012087772A1 (en) 2010-12-21 2012-06-28 Schering Corporation Indazole derivatives useful as erk inhibitors
WO2012143879A1 (en) 2011-04-21 2012-10-26 Piramal Healthcare Limited A crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation
EP2770987B1 (en) 2011-10-27 2018-04-04 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
EP2773207B1 (en) 2011-10-31 2018-03-07 Merck Sharp & Dohme Corp. Aminopyrimidinones as interleukin receptor-associated kinase inhibitors
DE102011055815A1 (de) 2011-11-29 2013-05-29 Aicuris Gmbh & Co. Kg Carboxamid-substituierte Heteroaryl-Pyrazole und ihre Verwendung
TW201331194A (zh) * 2011-12-23 2013-08-01 Millennium Pharm Inc 雜芳基化合物及其用途
EP3919620A1 (en) 2012-05-02 2021-12-08 Sirna Therapeutics, Inc. Short interfering nucleic acid (sina) compositions
BR112015002078A8 (pt) * 2012-07-30 2018-03-06 Univ Ohio State método de fabricação de inibidores de proteína quinase
DE102012016908A1 (de) 2012-08-17 2014-02-20 Aicuris Gmbh & Co. Kg Tris-(Hetero)Aryl-Pyrazole und ihre Verwendung
CA2882950A1 (en) 2012-09-28 2014-04-03 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
WO2014059333A1 (en) 2012-10-12 2014-04-17 Calcimedica, Inc. Compounds that modulate intracellular calcium
SMT201700595T1 (it) 2012-11-28 2018-03-08 Merck Sharp & Dohme Composizioni e metodi per trattare il cancro
WO2014100065A1 (en) 2012-12-20 2014-06-26 Merck Sharp & Dohme Corp. Substituted imidazopyridines as hdm2 inhibitors
WO2014120748A1 (en) 2013-01-30 2014-08-07 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as hdm2 inhibitors
CN103265537B (zh) * 2013-05-14 2015-05-27 浙江医药高等专科学校 抗肿瘤化合物、其制备方法和用途
US20160166576A1 (en) 2013-07-11 2016-06-16 Merck Sharp & Dohme Corp. Substituted amidopyrazole inhibitors of interleukin receptor-associated kinases (irak-4)
MA38849B1 (fr) 2013-07-31 2018-09-28 Council Scient Ind Res Nouveaux composés d'indazole pour le traitement du diabete et leur procede de preparation
WO2015034925A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Circular polynucleotides
WO2015054283A1 (en) 2013-10-08 2015-04-16 Calcimedica, Inc. Compounds that modulate intracellular calcium
JO3589B1 (ar) 2014-08-06 2020-07-05 Novartis Ag مثبطات كيناز البروتين c وطرق استخداماتها
KR101650476B1 (ko) * 2015-02-06 2016-08-23 한국건설기술연구원 중공슬래브를 위한 중공체의 부력방지장치
US10155765B2 (en) 2015-03-12 2018-12-18 Merck Sharp & Dohme Corp. Carboxamide inhibitors of IRAK4 activity
US10040802B2 (en) 2015-03-12 2018-08-07 Merck Sharp & Dohme Corp. Thienopyrazine inhibitors of IRAK4 activity
US10329294B2 (en) 2015-03-12 2019-06-25 Merck Sharp & Dohme Corp. Pyrazolopyrimidine inhibitors of IRAK4 activity
US10975084B2 (en) 2016-10-12 2021-04-13 Merck Sharp & Dohme Corp. KDM5 inhibitors
AR112900A1 (es) * 2017-09-13 2019-12-26 Hanmi Pharm Ind Co Ltd Compuesto derivado de pirazol y uso de este
WO2019094312A1 (en) 2017-11-08 2019-05-16 Merck Sharp & Dohme Corp. Prmt5 inhibitors
EP3706742B1 (en) 2017-11-08 2023-03-15 Merck Sharp & Dohme LLC Prmt5 inhibitors
CA3108388A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
WO2020033282A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
EP3833667B1 (en) 2018-08-07 2024-03-13 Merck Sharp & Dohme LLC Prmt5 inhibitors
WO2020033285A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
US12479816B2 (en) 2019-02-08 2025-11-25 University of Pittsburgh—of the Commonwealth System of Higher Education 20-HETE formation inhibitors
ES3022307T3 (en) 2019-12-17 2025-05-28 Merck Sharp & Dohme Llc Prmt5 inhibitors
ES3074517T3 (en) 2019-12-17 2026-07-21 Merck Sharp & Dohme Llc 4-(3,4-dihydroisoquinolin-2(1h)-yl)-3-hydroxypiperidine derivatives as prmt5 inhibitors for the treatment of cancer and sickle cell disease
EP4076459B1 (en) 2019-12-17 2026-04-29 Merck Sharp & Dohme LLC Prmt5 inhibitors
EP4076460B1 (en) 2019-12-17 2026-01-21 Merck Sharp & Dohme LLC 1,4-dihydro-2h-spiro[isoquinoline-3,4'-piperidine derivatives as prmt5 inhibitors for the treatment of cancer
CN112961109B (zh) * 2021-01-27 2022-05-17 台州学院 一种1，4-双磺酰化的全取代吡唑类化合物及其制备和应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4146721A (en) * 1969-09-12 1979-03-27 Byk Gulden Lomberg Chemische Fabrik Gmbh Pyrazol-4-acetic acid compounds
DE2536003C2 (de) * 1975-08-08 1985-11-14 Schering AG, 1000 Berlin und 4709 Bergkamen Pyrazol-Derivate, ihre Herstellung und diese enthaltende pharmazeutische Derivate
DE2906252A1 (de) * 1979-02-19 1980-08-28 Merck Patent Gmbh Pyrazolderivate, diese enthaltende pharmazeutische zubereitungen und verfahren zu ihrer herstellung
CA1130808A (en) * 1979-10-05 1982-08-31 Ronald G. Micetich 3-(or 5-) trifluoromethyl-1-aryl pyrazoles
JPS58177977A (ja) * 1982-04-09 1983-10-18 Grelan Pharmaceut Co Ltd ４−フエニルピラゾ−ル類
DE3575130D1 (de) * 1984-05-12 1990-02-08 Fisons Plc Antiinflammatorische 1,n-diarylpyrazol-3-amine, deren zusammensetzungen und verfahren zu deren herstellung.
JPS6140266A (ja) * 1984-08-01 1986-02-26 Morishita Seiyaku Kk ピラゾ−ル誘導体
US4826868A (en) * 1986-05-29 1989-05-02 Ortho Pharmaceutical Corporation 1,5-Diaryl-3-substituted pyrazoles pharmaceutical compositions and use
US5078780A (en) * 1986-10-22 1992-01-07 Ciba-Geigy Corporation 1,5-diphenylpyrazole-3-carboxylic acid derivatives for the protection of cultivated plants
EP0272704A3 (en) * 1986-12-26 1990-11-22 Sanwa Kagaku Kenkyusho Co., Ltd. Use of pyrazole derivatives in the treatment of immunity diseases and nephropathy
JPS6425763A (en) * 1987-04-24 1989-01-27 Mitsubishi Chem Ind Pyrazoles and insecticide and acaricide containing said pyrazoles as active ingredient
AU611437B2 (en) * 1987-05-29 1991-06-13 Ortho Pharmaceutical Corporation Pharmacologically active 2- and 3-substituted (1',5'-diaryl-3-pyrazolyl)-n-hydroxypropanamides and method for synthesizing the same
JPH089541B2 (ja) * 1988-03-07 1996-01-31 三井東圧化学株式会社 ピラゾール類を主成分とする脳浮腫抑制剤

Also Published As

Publication number Publication date
HU211532A9 (en) 1995-11-28
NO904134D0 (no) 1990-09-21
CN1046506C (zh) 1999-11-17
RU2059622C1 (ru) 1996-05-10
PT95389B (pt) 1998-06-30
KR0182798B1 (ko) 1999-05-01
FI904602A0 (fi) 1990-09-19
GR3017100T3 (en) 1995-11-30
ATE126216T1 (de) 1995-08-15
NO904134L (no) 1991-03-25
JP2586713B2 (ja) 1997-03-05
CA2025599C (en) 2001-11-20
IE903379A1 (en) 1991-04-10
JPH03141261A (ja) 1991-06-17
PT95389A (pt) 1991-05-22
FI102535B (fi) 1998-12-31
AU637142B2 (en) 1993-05-20
AU6307290A (en) 1991-04-18
DE69021472D1 (de) 1995-09-14
IE68857B1 (en) 1996-07-24
IL95675A (en) 1996-03-31
DK0418845T3 (da) 1995-09-18
EP0418845B1 (en) 1995-08-09
HUT57733A (en) 1991-12-30
EP0418845A1 (en) 1991-03-27
HU208122B (en) 1993-08-30
KR910006236A (ko) 1991-04-27
HU905970D0 (en) 1991-03-28
NO301006B1 (no) 1997-09-01
PH27357A (en) 1993-06-21
CN1050382A (zh) 1991-04-03
DE69021472T2 (de) 1996-01-25
RU2021990C1 (ru) 1994-10-30
CA2025599A1 (en) 1991-03-23
FI102535B1 (fi) 1998-12-31
IL95675A0 (en) 1991-06-30
US5134142A (en) 1992-07-28

Similar Documents

Publication Publication Date Title
NO904134L (no) Fremgangsmaate for fremstilling av pyrazolderivater.
ES2137169T3 (es) Nuevos derivados de tiazolilbenzofurano, procedimientos para su preparacion y composicion farmaceutica que los contiene.
MX9300579A (es) Derivados de pirazol, procedimientos para la preparacion de los mismos y a las composiciones farmaceuticas que comprenden a los mismos.
ES2082805T3 (es) Derivados de tiazol, procedimientos para su produccion y composiciones farmaceuticas que comprenden los mismos.
MX9202142A (es) Nuevos derivados de urea, proceso para su preparacion, y composicion farmaceutica que los comprende.
ES2185635T3 (es) Derivados de benzamida y su uso como antagonistas de vasopresina.
MX9306831A (es) Nuevos compuestos heterociclicos.
DE69008366D1 (de) 2-Aminopyrimidinon-Derivate.
ES2010284A6 (es) Procedimiento para preparar derivados de tiourea.
NO973213L (no) Nye 2-(1H)-quinolinforbindelser, fremgangsmåter ved fremstilling av slike samt farmasöytiske sammensetninger omfattende disse
ES2141134T3 (es) Derivados de carbamoil pirrolidona para el tratamiento de la depresion y de los trastornos cerebrovasculares.
DK168284A (da) Troponderivater

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 418845

Country of ref document: ES

FG2A Definitive protection

Ref document number: 418845

Country of ref document: ES